Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
COPD Asthma
Interventions
DEVICE

Spirometry at initial visit

Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.

DRUG

Albuterol

The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.

DEVICE

Spirometry at 12-month follow-up

At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.

Trial Locations (2)

60612

CCHHS, Chicago

UI Health, Chicago

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

University of Illinois at Chicago

OTHER

NCT03137303 - Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study) | Biotech Hunter | Biotech Hunter